Company:  BIOPHARMX CORP (BPMX)
Form Type:  10-K
Filing Date:  4/21/2017 
CIK:  0001504167 
Address:  1505 ADAMS DRIVE, SUITE D 
City, State, Zip:  MENLO PARK, California 94025 
Telephone:  650-889-5020 
Fiscal Year:  01/31 
Last Trade
Last Trade: 
$0.12  
Change: 
-0.0633 (-34.05%)  
Trade Time: 
03:46 PM EST  
Market Cap: 
$9.80M
Trade BPMX now with 

© 2017  
Description of Business
We are a specialty pharmaceutical company focused on utilizing our proprietary drug delivery technologies to develop and commercialize novel prescription products that address large markets in dermatology. Our objective is to develop products that treat health or age­related conditions that: (1) are not presently being addressed or treated or (2) are currently treated with drug therapies or drug delivery approaches that are sub­optimal.
Register and access this filing in:     
  FORM 10-K
    PART I
      ITEM 1. BUSINESS
      ITEM 1A. RISK FACTORS
      ITEM 1B. UNRESOLVED STAFF COMMENTS
      ITEM 2. PROPERTIES
      ITEM 3. LEGAL PROCEEDINGS
      ITEM 4. MINE SAFETY DISCLOSURES
    PART II
      ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED ...
      ITEM 6. SELECTED FINANCIAL DATA
      ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
        Results of Operations
        Liquidity and Capital Resources
      ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
      ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ...
      ITEM 9A. CONTROLS AND PROCEDURES
      ITEM 9B. OTHER INFORMATION
    PART III
      ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
        NAME AND TITLE
      ITEM 11. EXECUTIVE COMPENSATION
        COMPENSATION TABLE
      ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND ...
        BENEFICIAL OWNERS
      ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND ...
      ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
    PART IV
      ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
    STOCKHOLDERS EQUITY
    CASH FLOW
    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 3.5
  EXHIBIT 10.11
  EXHIBIT 10.23
  EXHIBIT 21.1
  EXHIBIT 23.1
    Consent of Independent Registered Public Accounting Firm
  EXHIBIT 31.1
    CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
  EXHIBIT 31.2
    CERTIFICATION OF CHIEF FINANCIAL OFFICER
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO